What are the clinical manifestations of Small Intestinal Bacterial Overgrowth (SIBO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Small intestinal bacterial overgrowth (SIBO) typically manifests with a range of gastrointestinal symptoms including bloating, abdominal distension, abdominal pain, diarrhea, and flatulence, as well as systemic symptoms such as fatigue, malabsorption, and vitamin deficiencies 1.

Clinical Manifestations

The clinical manifestations of SIBO can vary depending on the extent of bacterial overgrowth, the specific bacterial species involved, and any underlying conditions that may have predisposed to SIBO.

  • Gastrointestinal symptoms: bloating, abdominal distension, abdominal pain, diarrhea, and flatulence
  • Systemic symptoms: fatigue, malabsorption, weight loss, and vitamin deficiencies (particularly B12, fat-soluble vitamins A, D, E, and K)
  • Steatorrhea (fatty stools) can occur when fat absorption is impaired
  • Food intolerances, especially to carbohydrates, as bacteria ferment these substances causing increased gas production and discomfort

Diagnosis and Treatment

Diagnosis is typically confirmed through breath testing (hydrogen or methane) or jejunal aspirate cultures, though clinical presentation plays a crucial role in suspecting this condition 1.

  • Antibiotic therapy, such as metronidazole, amoxicillin-clavulanate, doxycycline, and norfloxacin, is often used to treat SIBO
  • Non-absorbable antibiotics, such as rifaximin, may also be used
  • Probiotics may be considered as an adjunctive therapy, although more research is needed to confirm their effectiveness

Management

The management of SIBO should prioritize the treatment of underlying conditions, such as intestinal motility disorders, anatomical abnormalities, or immunodeficiency states, in addition to antibiotic therapy 1.

  • Antidiarrheal drugs, such as loperamide, may be used for symptomatic relief
  • Bile salt sequestrants, such as cholestyramine, may be used to treat bile salt malabsorption
  • Octreotide may be used to reduce secretions and slow gastrointestinal motility in refractory cases of SIBO.

From the Research

Clinical Manifestations of Small Intestinal Bacterial Overgrowth

  • The clinical manifestations of small intestinal bacterial overgrowth (SIBO) can vary, but common symptoms include bloating, flatulence, abdominal distention, abdominal pain, and diarrhea 2, 3, 4.
  • Severe cases of SIBO may present with nutritional deficiencies due to malabsorption of micro- and macronutrients 3.
  • Abdominal bloating, gas, distension, and diarrhea are common symptoms, but they do not predict a positive diagnosis of SIBO 4.
  • Predisposing factors for SIBO include proton-pump inhibitors, opioids, gastric bypass, colectomy, and dysmotility 4.

Diagnostic Criteria and Methods

  • The current accepted criteria for the diagnosis of SIBO is the presence of coliform bacteria isolated from the proximal jejunum with >10^5 colony-forming units/mL 3.
  • Diagnostic methods include small bowel aspirate/culture, glucose or lactulose breath testing, and rapid molecular sequencing 3, 4.
  • Glucose or lactulose breath testing is noninvasive but an indirect method that requires further standardization and validation for SIBO 4.

Treatment Options

  • Treatment of SIBO usually involves antibiotics, aiming to provide symptom relief through eradication of bacteria in the small intestine 4.
  • Systemic antibiotics such as norfloxacin and metronidazole have been shown to be efficacious in limited numbers of controlled studies 4.
  • Rifaximin, a nonsystemic antibiotic, has been shown to be effective against SIBO and well tolerated in 15 studies 4.
  • High doses of rifaximin (1600 mg/day) have been shown to be more effective than lower doses (1200 mg/day) in treating SIBO, with a decontamination rate of 80% and low side-effects incidence 5.
  • Rifaximin may be a highly effective therapy in providing symptom relief from the effects of SIBO, particularly for patients with hydrogen-positive SIBO 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Small intestinal bacterial overgrowth: a comprehensive review.

Gastroenterology & hepatology, 2007

Research

Diagnosis and management of small intestinal bacterial overgrowth.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2013

Research

Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.

Clinical and translational gastroenterology, 2019

Research

Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.